SPLENIC MARGINAL ZONE LYMPHOMA
Clinical trials for SPLENIC MARGINAL ZONE LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new SPLENIC MARGINAL ZONE LYMPHOMA trials appear
Sign up with your email to follow new studies for SPLENIC MARGINAL ZONE LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising drug cocktail targets rare lymphoma in major trial
Disease control OngoingThis phase 2 trial tests a combination of two drugs, ibrutinib and rituximab, in people with untreated marginal zone lymphoma (a slow-growing blood cancer). About 175 participants will receive the treatment to see if it improves complete response rates at 12 months and progressio…
Matched conditions: SPLENIC MARGINAL ZONE LYMPHOMA
Phase: PHASE2 • Sponsor: International Extranodal Lymphoma Study Group (IELSG) • Aim: Disease control
Last updated May 17, 2026 07:39 UTC
-
New hope for relapsed lymphoma: drug cocktail targets cancer cells
Disease control OngoingThis early-stage trial tests a new drug (PCI-32765) combined with two standard treatments (rituximab and bendamustine) in 48 adults with relapsed non-Hodgkin lymphoma. The goal is to find the safest dose and see how well the combination works. Participants have specific types of …
Matched conditions: SPLENIC MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: Kami Maddocks, MD • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Engineered T-Cells show promise in lymphoma fight
Disease control OngoingThis early-phase study tests a new immune therapy for people with high-risk or returning non-Hodgkin lymphoma. After a stem cell transplant, patients receive specially modified T-cells designed to find and attack cancer cells. The main goal is to check safety and find the best do…
Matched conditions: SPLENIC MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New CMV strategy aims to protect stem cell transplant patients from dangerous infection
Disease control OngoingThis study looks at a modified approach to prevent and treat cytomegalovirus (CMV) infection in people who have had a donor stem cell transplant for blood cancers or disorders. About 153 participants are involved, and the goal is to see if changing when and how anti-CMV drugs are…
Matched conditions: SPLENIC MARGINAL ZONE LYMPHOMA
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New combo therapy aims to outperform standard treatment for rare blood cancer
Disease control OngoingThis study tests whether adding zanubrutinib to standard rituximab works better than rituximab alone for people with a rare lymphoma of the spleen (SMZL) who haven't had treatment yet. About 122 participants will receive either the combo or rituximab alone for up to 2 years, with…
Matched conditions: SPLENIC MARGINAL ZONE LYMPHOMA
Phase: PHASE3 • Sponsor: International Extranodal Lymphoma Study Group (IELSG) • Aim: Disease control
Last updated May 08, 2026 12:01 UTC